Aspira Pathlab & Diagnostics Ltd: Intrinsic Value & Share Price Analysis

Q: What is the current share price and 52-week range of Aspira Pathlab & Diagnostics Ltd?

Aspira Pathlab & Diagnostics Ltd is trading at 64.90 as of 05 May 2026, with a FY2026-2027 high of 81.0 and low of 49.0. The stock is currently in the middle of its 52-week range. Market cap stands at 66.8 Cr..

Q: Is Aspira Pathlab & Diagnostics Ltd financially healthy?

Key indicators: ROCE of 17.4 % indicates efficient capital utilization. Dividend yield is 0.00 %.

Q: Is Aspira Pathlab & Diagnostics Ltd profitable and how is the profit trend?

Aspira Pathlab & Diagnostics Ltd reported a net profit of 2 Cr in Mar 2025 on revenue of 22 Cr. Compared to 4 Cr in Mar 2022, the net profit shows a declining trend.

Fair Value

₹174.27Undervalued by 168.52%vs CMP ₹64.90

P/E (45.4) × ROE (33.6%) × BV (₹14.00) × DY (2.00%)

₹55.05Overvalued by 15.18%vs CMP ₹64.90

MoS: -17.9% (Negative)Confidence: 56/100 (Moderate)Models: 1 Under, 6 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹139.63	29%	Under (+115.1%)
Graham Number	Earnings	₹21.22	17%	Over (-67.3%)
DCF	Cash Flow	₹11.04	17%	Over (-83%)
Net Asset Value	Assets	₹14.01	9%	Over (-78.4%)
EV/EBITDA	Enterprise	₹46.02	11%	Over (-29.1%)
Earnings Yield	Earnings	₹14.30	9%	Over (-78%)
Revenue Multiple	Revenue	₹21.37	7%	Over (-67.1%)
Consensus (7 models)		₹55.05	100%	Overvalued

Key Drivers: EPS CAGR -19.9% drags value — could be higher if earnings stabilize. | Wide model spread (₹11–₹140) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -19.9%

*Investments are subject to market risks

Analyst Summary

Aspira Pathlab & Diagnostics Ltd operates in the Hospitals & Medical Services segment, NSE: ASPIRA | BSE: 540788, current market price is ₹64.90, market cap is 66.8 Cr.. At a glance, stock P/E is 45.4, ROE is 33.6 %, ROCE is 17.4 %, book value is 14.0, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹55.05, around 15.2% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹22 Cr versus the prior period change of 66.7%, while latest net profit is about ₹2 Cr with a prior-period change of 177.5%. The 52-week range shown on this page is 81.0/49.0, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisAspira Pathlab & Diagnostics Ltd. is a Public Limited Listed company incorporated on 03/07/1973 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Num…

This summary is generated from the stock page data available for Aspira Pathlab & Diagnostics Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

Aspira Pathlab & Diagnostics Ltd scores 67/100 (Average)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health75/100 · Strong

ROCE 17.4% GoodROE 33.6% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 3/5 years Mixed

Smart Money50/100 · Moderate

Promoter holding at 18.4% Stable

Earnings Quality50/100 · Moderate

OPM contracting (22% → 4%) DecliningWorking capital: 14 days (improving) Efficient

Quarterly Momentum80/100 · Strong

Revenue (4Q): +21% YoY AcceleratingProfit (4Q): +73% YoY StrongOPM: -23.6% (down 37.7% YoY) Margin pressure

Industry Rank70/100 · Strong

P/E 45.4 vs industry 84.8 Cheaper than peersROCE 17.4% vs industry 14.7% AverageROE 33.6% vs industry 13.9% Above peers3Y sales CAGR: 4% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: May 5, 2026, 2:17 am

Market Cap	66.8 Cr.
Current Price	64.9
Intrinsic Value	₹57.17
High / Low	81.0/49.0
Stock P/E	45.4
Book Value	14.0
Dividend Yield	0.00 %
ROCE	17.4 %
ROE	33.6 %
Face Value	10.0
PEG Ratio	-2.28

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Aspira Pathlab & Diagnostics Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Aspira Pathlab & Diagnostics Ltd	66.8 Cr.	64.9	81.0/49.0	45.4	14.0	0.00 %	17.4 %	33.6 %	10.0
Dr Lal Pathlabs Ltd	26,346 Cr.	1,573	1,771/1,272	49.9	150	0.76 %	28.3 %	22.5 %	10.0
Thyrocare Technologies Ltd	6,687 Cr.	420	538/291	50.9	32.4	1.67 %	26.5 %	17.4 %	10.0
Artemis Medicare Services Ltd	3,948 Cr.	250	298/203	39.7	56.0	0.18 %	14.9 %	12.9 %	1.00
Sakar Healthcare Ltd	1,452 Cr.	652	662/264	57.6	136	0.00 %	8.54 %	6.48 %	10.0
Industry Average	27,402.00 Cr	671.38		84.84	84.04	0.34%	14.71%	13.94%	9.04

All Competitor Stocks of Aspira Pathlab & Diagnostics Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	4.37	3.41	2.60	3.32	3.46	3.82	4.64	6.18	5.41	5.78	5.25	8.09	5.12
Expenses	3.56	3.26	2.92	3.68	3.83	3.95	4.29	4.83	4.65	4.73	4.44	5.90	6.33
Operating Profit	0.81	0.15	-0.32	-0.36	-0.37	-0.13	0.35	1.35	0.76	1.05	0.81	2.19	-1.21
OPM %	18.54%	4.40%	-12.31%	-10.84%	-10.69%	-3.40%	7.54%	21.84%	14.05%	18.17%	15.43%	27.07%	-23.63%
Other Income	0.12	0.07	0.10	0.14	0.10	0.08	0.09	0.08	0.09	0.13	0.11	0.14	0.13
Interest	0.10	0.10	0.10	0.10	0.09	0.08	0.08	0.08	0.09	0.09	0.09	0.10	0.10
Depreciation	0.39	0.38	0.39	0.39	0.38	0.38	0.38	0.36	0.39	0.37	0.37	0.40	0.38
Profit before tax	0.44	-0.26	-0.71	-0.71	-0.74	-0.51	-0.02	0.99	0.37	0.72	0.46	1.83	-1.56
Tax %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	0.44	-0.26	-0.72	-0.71	-0.74	-0.50	-0.02	0.99	0.38	0.72	0.47	1.84	-1.56
EPS in Rs	0.43	-0.25	-0.70	-0.69	-0.72	-0.49	-0.02	0.96	0.37	0.70	0.46	1.79	-1.52

Last Updated: March 3, 2026, 12:08 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 11:05 pm

Metric	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	0.00	0.00	0.00	0.76	4.36	7.64	8.42	15.21	19.54	14.46	13.20	22.00	24.24
Expenses	0.02	0.14	0.23	3.34	8.24	10.88	10.25	11.69	13.16	12.86	14.38	18.44	21.40
Operating Profit	-0.02	-0.14	-0.23	-2.58	-3.88	-3.24	-1.83	3.52	6.38	1.60	-1.18	3.56	2.84
OPM %				-339.47%	-88.99%	-42.41%	-21.73%	23.14%	32.65%	11.07%	-8.94%	16.18%	11.72%
Other Income	0.02	0.21	0.32	0.31	0.22	0.25	0.29	0.20	0.09	0.32	0.42	0.36	0.51
Interest	0.00	0.00	0.05	0.26	0.80	0.96	1.01	0.89	0.37	0.42	0.37	0.35	0.38
Depreciation	0.00	0.00	0.00	0.20	1.12	1.23	1.66	1.44	1.64	1.59	1.54	1.49	1.52
Profit before tax	0.00	0.07	0.04	-2.73	-5.58	-5.18	-4.21	1.39	4.46	-0.09	-2.67	2.08	1.45
Tax %		57.14%	25.00%	0.00%	0.00%	0.00%	0.71%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	0.00	0.02	0.03	-2.72	-5.58	-5.18	-4.24	1.38	4.46	-0.09	-2.67	2.07	1.47
EPS in Rs	0.00	0.09	0.13	-5.24	-10.75	-6.32	-4.56	1.34	4.33	-0.09	-2.59	2.01	1.43
Dividend Payout %		0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	50.00%	-9166.67%	-105.15%	7.17%	18.15%	132.55%	223.19%	-102.02%	-2866.67%	177.53%
Change in YoY Net Profit Growth (%)	0.00%	-9216.67%	9061.52%	112.32%	10.98%	114.40%	90.64%	-325.21%	-2764.65%	3044.19%

Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	21%
3 Years:	4%
TTM:	48%

Compounded Profit Growth
10 Years:	59%
5 Years:	20%
3 Years:	-23%
TTM:	230%

Stock Price CAGR
10 Years:	%
5 Years:	26%
3 Years:	13%
1 Year:	99%

Return on Equity
10 Years:	%
5 Years:	17%
3 Years:	-3%
Last Year:	24%

Last Updated: September 5, 2025, 2:26 pm

Balance Sheet

Last Updated: February 1, 2026, 2:23 am

Month	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	0.40	2.25	2.25	5.19	5.19	8.19	9.29	10.29	10.29	10.29	10.29	10.29	10.29
Reserves	0.19	1.36	1.39	0.72	-4.86	-7.93	-10.42	-6.91	-2.43	-2.47	-5.08	-3.01	4.13
Borrowings	0.00	0.00	2.62	7.29	11.36	12.52	13.80	7.01	8.85	8.24	7.71	8.13	3.13
Other Liabilities	0.03	0.21	0.03	1.66	0.84	2.02	1.67	1.39	1.42	1.28	1.79	2.11	2.61
Total Liabilities	0.62	3.82	6.29	14.86	12.53	14.80	14.34	11.78	18.13	17.34	14.71	17.52	20.16
Fixed Assets	0.00	0.00	0.04	7.79	7.91	8.90	8.70	7.75	9.57	8.01	6.79	6.53	6.71
CWIP	0.00	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13	0.00
Other Assets	0.62	3.82	6.25	6.82	4.62	5.90	5.64	4.03	8.56	9.33	7.92	10.86	13.45
Total Assets	0.62	3.82	6.29	14.86	12.53	14.80	14.34	11.78	18.13	17.34	14.71	17.52	20.16

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2012	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	-0.02	-0.37	-1.29	-4.81	-3.39	-1.87	5.67	2.03	-0.01	1.05	1.88
Cash from Investing Activity +	0.08	-0.02	-10.14	-0.77	-1.97	0.24	-0.09	-0.51	0.16	0.14	0.07
Cash from Financing Activity +	-0.06	2.64	8.91	6.52	3.35	1.27	-2.17	-1.35	-0.94	-0.95	-0.99
Net Cash Flow	0.00	2.25	-2.52	0.94	-2.00	-0.35	3.41	0.17	-0.79	0.24	0.95
Free Cash Flow	-0.02	-0.41	-8.41	-5.81	-3.90	-1.92	5.37	1.42	-0.15	0.79	1.71
CFO/OP	50%	139%	50%	124%	105%	101%	161%	32%	-1%	-89%	53%

Free Cash Flow

Month	Mar 2012	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-0.02	-0.14	-2.85	-9.87	-15.24	-15.76	-15.63	-3.49	-2.47	-6.64	-8.89	-4.57

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2012	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days			43.22	29.30	38.22	26.01	40.80	83.87	59.07	61.94	38.99
Inventory Days			312.86	103.88	45.22	51.36	51.35	46.50	58.40	62.69	50.31
Days Payable			730.00	64.58	46.84	73.37	91.60	70.91	51.10	101.70	73.00
Cash Conversion Cycle			-373.92	68.61	36.60	4.00	0.55	59.46	66.37	22.93	16.30
Working Capital Days			-2,199.61	-5.86	-96.03	-127.01	16.32	69.30	48.72	25.16	14.10
ROCE %	0.00%	1.82%	-25.39%	-38.41%	-34.49%	-25.15%	19.77%	35.65%	2.01%	-15.87%	17.37%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	19.47%	19.37%	18.90%	18.90%	18.72%	18.72%	18.55%	18.55%	18.39%	18.39%	18.39%	18.39%
Public	80.53%	80.64%	81.10%	81.10%	81.29%	81.28%	81.46%	81.46%	81.62%	81.62%	81.61%	81.61%
No. of Shareholders	1,300	1,371	1,406	1,351	1,512	1,695	1,706	1,593	1,741	1,770	1,755	1,784

Shareholding Pattern Chart

No. of Shareholders

Aspira Pathlab & Diagnostics Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24
FaceValue	10.00	10.00
Basic EPS (Rs.)	1.97	-2.60
Diluted EPS (Rs.)	1.97	-2.60
Cash EPS (Rs.)	3.46	-1.10
Book Value[Excl.RevalReserv]/Share (Rs.)	7.03	5.07
Book Value[Incl.RevalReserv]/Share (Rs.)	7.03	5.07
Revenue From Operations / Share (Rs.)	21.37	12.83
PBDIT / Share (Rs.)	3.80	-0.74
PBIT / Share (Rs.)	2.35	-2.24
PBT / Share (Rs.)	2.01	-2.60
Net Profit / Share (Rs.)	2.01	-2.60
NP After MI And SOA / Share (Rs.)	1.97	-2.60
PBDIT Margin (%)	17.79	-5.79
PBIT Margin (%)	11.00	-17.45
PBT Margin (%)	9.42	-20.23
Net Profit Margin (%)	9.42	-20.23
NP After MI And SOA Margin (%)	9.19	-20.23
Return on Networth / Equity (%)	27.94	-51.25
Return on Capital Employeed (%)	16.03	-18.23
Return On Assets (%)	11.58	-18.16
Asset Turnover Ratio (%)	1.37	0.00
Current Ratio (X)	2.26	2.10
Quick Ratio (X)	2.05	1.89
Inventory Turnover Ratio (X)	45.90	0.00
Interest Coverage Ratio (X)	11.27	-2.08
Interest Coverage Ratio (Post Tax) (X)	6.97	-6.27
Enterprise Value (Cr.)	86.79	31.60
EV / Net Operating Revenue (X)	3.95	2.39
EV / EBITDA (X)	22.18	-41.27
MarketCap / Net Operating Revenue (X)	3.99	2.42
Price / BV (X)	12.12	6.12
Price / Net Operating Revenue (X)	3.99	2.42
EarningsYield	0.02	-0.08

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Aspira Pathlab & Diagnostics Ltd. is a Public Limited Listed company incorporated on 03/07/1973 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L85100MH1973PLC289209 and registration number is 289209. Currently Company is involved in the business activities of Other human health activities. Company's Total Operating Revenue is Rs. 22.00 Cr. and Equity Capital is Rs. 10.29 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Hospitals & Medical Services	Flat No.2, R.D. Shah Building, Mumbai Maharashtra 400086	Contact not found

Management
Name	Position Held
Dr. Haseeb A Drabu	Chairman & Ind.Director
Dr. Pankaj J Shah	Managing Director & CEO
Mr. Nikunj V Mange	Executive Director
Mrs. Mangala R Prabhu	Independent Director
Dr. Manas R Mengar	Independent Director

FAQ

What is the intrinsic value of Aspira Pathlab & Diagnostics Ltd and is it undervalued?

As of 05 May 2026, Aspira Pathlab & Diagnostics Ltd's intrinsic value is ₹55.05, which is 15.18% lower than the current market price of ₹64.90, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (33.6 %), book value (₹14.0), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Aspira Pathlab & Diagnostics Ltd?

Aspira Pathlab & Diagnostics Ltd is trading at ₹64.90 as of 05 May 2026, with a FY2026-2027 high of ₹81.0 and low of ₹49.0. The stock is currently in the middle of its 52-week range. Market cap stands at ₹66.8 Cr..

How does Aspira Pathlab & Diagnostics Ltd's P/E ratio compare to its industry?

Aspira Pathlab & Diagnostics Ltd has a P/E ratio of 45.4, which is below the industry average of 84.84. This is broadly in line with or below the industry average.

Is Aspira Pathlab & Diagnostics Ltd financially healthy?

Key indicators for Aspira Pathlab & Diagnostics Ltd: ROCE of 17.4 % indicates efficient capital utilization; ROE of 33.6 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Aspira Pathlab & Diagnostics Ltd profitable and how is the profit trend?

Aspira Pathlab & Diagnostics Ltd reported a net profit of ₹2 Cr in Mar 2025 on revenue of ₹22 Cr. Compared to ₹4 Cr in Mar 2022, the net profit shows a declining trend.

Does Aspira Pathlab & Diagnostics Ltd pay dividends?

Aspira Pathlab & Diagnostics Ltd has a dividend yield of 0.00 % at the current price of ₹64.90. The company is currently not paying meaningful dividends.